“The addition of this well respected Boston cancer center will enable enrollment of patients from the New England area who are suffering from this terrible late-stage cancer, and will substantially enhance the pace of enrollment in this clinical trial of Atiprimod,” said Dr Gary Jacob, CEO of Callisto.
Other major cancer centers are currently reviewing the trial protocol and the company anticipates that additional sites will open in the near future.
The primary objective of the phase II trial is to evaluate efficacy of Atiprimod in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable cancer and who have progression of their disease despite standard therapy.